## Records ?

## Pediatric Kidney-Pancreas Transplant Recipient Follow-Up Worksheet

The revised worksheet sample is for reference purposes only and is pending OMB approval.

Note: These worksheets are provided to function as a guide to what data will be required in the online TIEDI<sup>B.</sup> application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online TIEDI<sup>B.</sup> application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

Recipient Information			
Name:	DOB:		
SSN:	Gender:		
HIC:	Tx Date:		
Previous Follow-Up:	Previous Px Stat Date:		
Transplant Discharge Date:			
State of Permanent Residence: ★			
Zip Code: <del>*</del>			
Zip oods.			
Provider Information			
Recipient Center:			
Followup Center:			
Physician Name: <del>*</del>			
NPI:*			
	Transplant Center		
5 W 0 D 11 ID W	Non Transplant Center Specialty Physician		
Follow-up Care Provided By: *	Primary Care Physician		
	Other Specify		
	Other Specify		
Specify:			
Donor Information			
UNOS Donor ID #:			
Donor Type:			
Patient Status			
Date: Last Seen, Retransplanted or Death★			
	LIVING		
Patient Status: *			
Patient Status: **	© DEAD		
	© RETRANSPLANTED		
If Retransplanted, choose organ(s):			
Primary Cause of Death:			
Specify:			
Contributory Cause of Death:			
Specify:			
Contributory Cause of Death:			
Specify:			
Hospitalizations:			
Has the patient been hospitalized since the last patient status date:*	C YES NO UNK		
	- 120 - NO - ONK		
Number of Hospitalizations:	St=		
Noncompliance:			
Was there evidence of noncompliance with immunosuppression medication during this follow-up period that compromised the patient's recovery:	© YES © NO © UNK		
Functional Status: *			
	Definite Cognitive delay/impairment (verified by IQ score <70 or unambiguous behavioral observation)		
	- Definite doginave delay/impairment (vermed by 19/50016 <70 or unambiguous behavioral observation)		

Cognitive Development: *	<ul> <li>Probable Cognitive delay/impairment (not verified or unambiguous but more likely than not, based on behavioral observation or other evidence)</li> <li>Questionable Cognitive delay/impairment (not judged to be more likely than not, but with some indication of cognitive delay/impairment such as expressive/receptive language and/or learning difficulties)</li> <li>No Cognitive delay/impairment (no obvious indicators of cognitive delay/impairment)</li> <li>Not Assessed</li> </ul>		
Motor Development: ★	<ul> <li>Definite Motor delay/impairment (verified by physical exam or unambiguous behavioral observation)</li> <li>Probable Motor delay/impairment (not verified or unambiguous but more likely than not, based on behavioral observation or other evidence)</li> <li>Questionable Motor delay/impairment (not judged to be more likely than not, but with some indications of motor delay/impairment)</li> <li>No Motor delay/impairment (no obvious indicators of motor delay/impairment)</li> <li>Not Assessed</li> </ul>		
Academic Progress: <del>*</del>	<ul> <li>Within One Grade Level of Peers</li> <li>Delayed Grade Level</li> <li>Special Education</li> <li>Not Applicable &lt; 5 years old</li> <li>Status Unknown</li> </ul>		
Academic Activity Level:*	<ul> <li>Full academic load</li> <li>Reduced academic load</li> <li>Unable to participate in academics due to disease or condition</li> <li>Not Applicable &lt; 5 years old/ High School graduate</li> <li>Status Unknown</li> </ul>		
Primary Insurance at Follow-up:*  Specify:			
Clinical Information			
Date of Measurement: *			
Height: <del>*</del>	ft in cm %ile St=		
Weight: <sup>★</sup>	lbs. kg %ile St=		
BMI:	kg/m <sup>2</sup> %ile		
Is growth hormone therapy used during this follow-up period: *	C YES NO C UNK		
Urine Protein Found By Any Method:	G YES O NO G UNK		
Bone Disease: *			
Fracture in the past year (or since last follow-up):	C YES NO UNK		
Specify Location and number of fractures:	Spine-compression fracture # of fractures:  Extremity # of fractures:  Other # of fractures:		
AVN (avascular necrosis):	G YES NO G UNK		
Kidney Graft Status: <del>*</del>	Functioning Failed		
If death is indicated for the recipient, and the death was a result of some of			
If Functioning, Most Recent Serum Creatinine:	mg/dl St=		
Kidney Date of Failure:			
Kidney Primary Cause of Graft Failure:			
Specify			
Contributory causes of graft failure:			

	Kidney Acute Rejection	C YES NO C UNK
	Kidney Chronic Rejection	© YES © NO © UNK
	Kidney Graft Thrombosis	G YES G NO G UNK
	Kidney Infection	G YES G NO G UNK
	Urological Complications	C YES NO UNK
	Patient Noncompliance	C YES NO UNK
	Recurrent Disease:	C YES NO UNK
	BK (Polyoma) Virus	C YES NO UNK
	Kidney Other Contributory Cause of Graft Failure	
		○ NO
		YES, RESUMED MAINTENANCE DIALYSIS
Dialy	rsis Since Last Follow-Up:	YES, NO MAINTENANCE RESUMPTION
		YES, MAINTENANCE RESUMPTION UNKNOWN
		UNKNOWN
	Date Maintenance Dialysis Resumed:	
	Salast a Dialysis Provider	
	Select a Dialysis Provider: Provider #:	
	Provider Name:	
	Flovider Name.	
Pano	creas Graft Status:*	Functioning Partial Function Failed
If dea	ath is indicated for the recipient, and the death was a result of some other factor	or unrelated to graft failure, select Functioning.
		_
		Insulin —
Me	ethod of blood sugar control:	Oral medication
		□ Diet
		No Treatment
	Date insulin/medication resumed:	
	Pancreas Date of Failure	
	Pancreas Graft Removed:	C YES NO UNK
	Date Pancreas Removed:	
	Pancreas Primary Causes of Graft Failure	
	Specify:	
	Contributory causes of graft failure:	
	Pancreas Graft/Vascular Thrombosis	G YES G NO G UNK
	Pancreas Infection	G YES G NO G UNK
	Pancreas Bleeding	€ YES € NO € UNK
	Anastomotic Leak	G YES G NO G UNK
	Pancreas Rejection: Acute	G YES G NO G UNK
	Pancreas Chronic Rejection	C YES NO UNK
	Biopsy Proven Isletitis	C YES NO UNK
	Pancreatitis	€ YES € NO € UNK
	Patient Noncompliance	© YES © NO © UNK
	Other, Specify:	

Conv. From Bladder to Enteric Drain Performed:*	€ YES € NO € UNK
Enteric Drain Date:	
Serum Amylase:	u/L St=
Pancreas Transplant Complications (Not leading to graft failure):	
Pancreatitis *	€ YES € NO € UNK
Anastomotic Leak*	C YES ONO UNK
Abcess or Local Infection <sup>★</sup>	© YES © NO © UNK
Other, Specify:	
Did patient have any kidney acute rejection episodes during the follow-up period:*	Yes, at least one episode treated with anti-rejection agent Yes, none treated with additional anti-rejection agent No Unknown
Was biopsy done to confirm acute rejection:	<ul> <li>Biopsy not done</li> <li>Yes, rejection confirmed</li> <li>Yes, rejection not confirmed</li> <li>Unknown</li> </ul>
Did patient have any pancreas acute rejection episodes during the follow-up period: ★	<ul> <li>Yes, at least one episode treated with anti-rejection agent</li> <li>Yes, none treated with additional anti-rejection agent</li> <li>No</li> <li>Unknown</li> </ul>
Was biopsy done to confirm acute rejection:	<ul> <li>Biopsy not done</li> <li>Yes, rejection confirmed</li> <li>Yes, rejection not confirmed</li> <li>Unknown</li> </ul>
CMV IgG: <b>≭</b>	Positive Negative Not Done UNK/Cannot Disclose
CMV IgM: <b>≭</b>	Positive Negative Not Done UNK/Cannot Disclose
Postransplant Malignancy:★	€ YES € NO € UNK
Donor Related:	C YES ONO UNK
Recurrence of Pre-Tx Tumor:	C YES NO UNK
De Novo Solid Tumor:	C YES ONO UNK
De Novo Lymphoproliferative disease and Lymphoma:	C YES NO UNK
Treatment	
Biological or Anti-viral therapy:	

☐ Acyclovir (Zovirax)

If Yes, check all that apply:	Cytogam (CMV) Gamimune Gammagard Ganciclovir (Cytovene) Valgancyclovir (Valcyte) HBIG (Hepatitis B Immune Globulin) Flu Vaccine (Influenza Virus) Lamivudine (Epivir) (for treatment of Hepatitis B) Valacyclovir (Valtrex) Other, Specify
Specify:	
Specify:	
Treatment for BK (polyoma) virus:	© YES © NO
If Yes, check all that apply:	<ul> <li>Yes, Immunosuppression reduction</li> <li>Yes, Cidofovir</li> <li>Yes, IVIG</li> <li>Yes, Type Unknown</li> <li>Yes, Other, Specify</li> </ul>
Specify:	
Other therapies:	C YES C NO
If Yes, check all that apply:	Photopheresis Plasmapheresis Total Lymphoid Irradiation (TLI)
Immunosuppressive Information	
Previous Validated Maintenance Follow-Up Medications:	
Were any medications given during the follow-up period for maintenance:*	<ul> <li>Yes, same as previous validated report</li> <li>Yes, but different than previous validated report</li> <li>None given</li> </ul>
Did the physician discontinue all maintenance immunosuppressive medications:	C YES NO
Did the patient participate in any clinical research protocol for immunosuppressive medications:	© YES © NO
Specify:	
Immunosuppressive Medications	
View Immunosuppressive Medications	
Definitions Of Immunosuppressive Follow-Up Medications	
Previous Maintenance (Prev Maint) includes all immunosuppressive medications periods of time which may be either long-term or intermediate term with a tapering Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or RaCurrent Maintenance (Curr Maint) includes all immunosuppressive medications intermediate term with a tapering of the dosage until the drug is either eliminated of Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive Anti-rejection (AR) immunosuppression includes all immunosuppressive medications (example: from the listed under AR immunosuppression, but should be listed under maintenance Note: The Anti-rejection field refers to any anti-rejection medications since the	e given during the report period, which covers the period from the last clinic visit to the current clinic visit, for varying of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug (example: pamycin). This does not include any immunosuppressive medications given to treat rejection episodes. given at the current clinic visit to begin in the next report for varying periods of time which may be either long-term or replaced by another long-term maintenance drug (example: Prednisone, Cyclosporine, Tacrolimus, Mycophenolate we medications given to treat rejection episodes.  ons given for the purpose of treating an acute rejection episode since the last clinic visit (example: Methylprednisolone, om Tacrolimus to Cyclosporine; or from Mycophenolate Mofetil to Azathioprine) because of rejection, the drugs should be immunosuppression.  the last clinic visit, not just at the time of the current clinic visit.  (e.g., new monoclonal antibodies), select Previous Maint, or Current Maint, or AR next to Other Immunosuppressive
	Prev Maint Gurr Maint AR

П		
П		
П		
		П
Prev Maint	Curr Maint	AR
Prev Maint	Curr Maint	AR
Prev Maint	Curr Maint	AR
Prev Maint	Curr Maint	AR
	Prev Maint	Prev Maint Curr Maint